Navigation Links
BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters

BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. delivered the keynote presentation on Wednesday, November 19, at a meeting in Madison, Wisconsin commemorating the 10th anniversary of the publication describing the first derivation and culturing of human embryonic stem cells. Dr. West’s presentation is titled “Opportunities and Challenges of Commercializing Stem Cell Research.” The Wisconsin Academy, along with University of Wisconsin-Madison and the Wisconsin Alumni Research Foundation (WARF), hosted the two-day event titled “A Decade Celebrating Stem Cells: Changing the Face of Medicine Ten Years Later” to commemorate the publication of the first derivation of human embryonic stem cells and to examine future trends.

ALAMEDA, Calif. (Business Wire EON) November 19, 2008 -- Dr. West's presentation included a historical overview of the biotechnology industry, a description of historical trends in the industry of commercializing stem cell technology, and a discussion of future opportunities for the field. Dr. West discussed BioTime's stem cell research program that is focused on opportunities for near-term revenues in the development and marketing of products derived from stem cells.

  • West announced the launch of ten new cell line products and presented data on their unique properties and potential utility in regenerative medicine. The molecular markers of these lines are consistent with varied types of human neural crest, mesodermal, and CNS progenitor cells that have promise for the treatment of numerous diseases such as cranial-facial, muscular, and neurological disorders. Information about these cell lines will be available online at starting Monday, November 24, 2008, and the cells themselves are now available for purchase for research purposes only through the same website.

Lastly, Dr. West discussed federal policies relating to the industry of regenerative medicine. He announced an open letter to President-Elect Obama signed by 22 scientists and economists (including 19 Nobel laureates), urging the new Administration to make regenerative medicine, specifically, the cure of human disease, a national priority, similar in scope to the Kennedy Administration's commitment to land a man on the moon within that decade. The text of the letter to President-Elect Obama is available online at

About BioTime, Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.

BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at Hextend, PentaLyte, HetaCool, EmbryomicsTM, ESpyTM, and ESpanTM, are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. BioTime, Inc. and Embryome Sciences, Inc. Launch and the International Embryome Initiative
2. Michael J. Fox Foundation Names Core Programs in Honor of Humanitarian Edmond J. Safra
3. Vocollect Healthcare Systems Names Michael French as Vice President of Customer Experience
4. UCSF Chancellor J. Michael Bishop Announces Plan To Step Down
5. Majesco Entertainment and Interactive Game Group Announce Jillian Michaels Fitness Ultimatum 2009 Ships to Stores October 21st
6. US Oncology Appoints Michael A. Sicuro Executive Vice President and Chief Financial Officer
7. Quorum Review IRB Appoints Michael Malafronte Director of Quality and Document Administration
8. Michael J. Fox Foundation Awards One Million Dollars for Development of Trojan Horse Delivery Technology to Treat Parkinsons Disease
9. Catholic Health East Acquires Saint Michaels Medical Center
10. Michael and Terry Ward Donate $1 Million to Wounded Warrior Project (WWP)
11. Rock The Cradles Bad Boy Landon Brown Owes His Irresistible New Smile to Dr. Michael Kosdon
Post Your Comments:
Related Image:
 BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters 
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: